Document is current
Any future updates will be listed below
-
Authors
Gossec, Laure
Patel, Jayesh
Kadakia, Aditi
Fang, Siran
Peng, Yi
Strengholt, Sander
Taylor, Peter C.
Östör, Andrew
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 17 May 2025
First Online: 13 June 2025
Declarations
:
: This study used data from the phase 3 trial SELECT-COMPARE, which was conducted as per the International Conference on Harmonisation guidelines, the Declaration of Helsinki, and any other applicable regulations. Study-related documents were approved by the US Central Institutional Review Board (Quorum #31009) and other local institutional ethics committees and review boards.
: All participants provided written consent for publication.
: Laure Gossec has received grants or contracts from AbbVie, Biogen, Lilly, Novartis, and UCB; consulting fees from AbbVie, BMS, Celltrion, Janssen, Novartis, Pfizer, and UCB; honoraria for lectures from AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, MSD, Novartis, Pfizer, Stada, and UCB; support for attending meetings and/or travel from Biogen, MSD, and Pfizer; medical writing support from AbbVie, Amgen, Janssen, Pfizer, and UCB; and serves as the EULAR treasurer. Jayesh Patel, Aditi Kadakia, Siran Fang, and Yi Peng are employees of AbbVie and may own stock, stock options, or patents. Sander Strengholt is a former employee of AbbVie and may own stock, stock options, or patents. Peter C. Taylor reports grants/contracts from Galapagos to University of Oxford; consulting fees from AbbVie, Biogen, Fresenius, Takeda, Galapagos, Gilead, Janssen, Lilly, Nordic Pharma, Pfizer, UCB, and Acelyrin Inc.; and participation on a Data Safety Monitoring Board/Advisory Board for Immunovant, Sanofi, and Moonlake. Andrew Östör has been a consultant, served on Advisory boards, and has undertaken clinical trials for AbbVie, Janssen, Lilly, Novartis, Pfizer, and GSK.
